2-Aminoindane

The current Alabama Administrative Code Chapter 420-7-2 controlled-substances list expressly names 2-aminoindane and the synonym 2-AI, with state control dated March 18, 2014; the chapter's amendment history is current through April 9, 2026. The current DEA controlled-substance reference (August 2026) contains no aminoindane match and warns that its lists are not comprehensive. Federal law therefore does not support the old categorical statement that possession is generally legal: 21 U.S.C. § 802(32) defines controlled-substance analogues by specified tests, and § 813 treats a qualifying analogue as Schedule I to the extent intended for human consumption. Those federal provisions do not themselves make a substance an analogue without a fact-specific determination, and this entry does not extend control to substituted or N-methyl aminoindanes.

Belgium places nationally listed amphetamine derivatives in Annex IVa of the Royal Decree of 6 September 2017 regulating narcotic and psychotropic substances. The annex defines derivatives of 1-phenylpropan-2-amine and permits the CnH2n+1 side-chain element to be incorporated into a ring structure linked to the phenyl or amine; 2-aminoindane (2,3-dihydro-1H-inden-2-amine) is the corresponding ring-closed scaffold. The AFMPS explains that Annex IVa uses a generic structural classification, so coverage is not limited to substances printed by name in its indicative list.

Israel’s Dangerous Drugs Ordinance [New Version], 5733–1973, covers 2-aminoindane through its First Schedule framework. An official Israel Anti-Drug Authority publication states that the Ordinance was expanded in 2011 to include the 2-aminoindan family, so qualifying structural derivatives are covered rather than only a single named molecule. The government’s 2014 Free Import Order separately places “2-amino-indane” in its Fourth Appendix list of dangerous and psychotropic drugs and notes that chemical derivatives defined by the Ordinance are included.

The Netherlands places substances derived from 2-phenethylamine in List IA, and the group's structure-element B expressly includes substitutions that can lead to ring closure with structure element A. 2-Aminoindane has that ring-closed 2-phenethylamine framework and is therefore covered by the generic List IA group rather than requiring a name listing. Article 2a prohibits importing, exporting, preparing, processing, selling, supplying, transporting, possessing, or manufacturing substances in a List IA group, subject to statutory exceptions.

Portugal lists 2-aminoindano (2,3-di-hidro-1H-inden-2-amina; or 1-aminoindan (2,3-di-hidro-1H-inden-1-amina)) as a new psychoactive substance in the annex republished by Portaria n.º 232/2022. Under Decreto-Lei n.º 54/2013, producing, importing, exporting, advertising, distributing, selling, possessing, or making listed new psychoactive substances available is prohibited, except for properly authorized industrial or pharmaceutical uses. The decree applies the Portuguese own-consumption framework to possession for mere personal consumption.

The current Singapore Statutes Online consolidation expressly places 2,3-Dihydro-1H-inden-2-amine (also known as 2-Aminoindane) at First Schedule Part 1, paragraph 18, item (31), under CLASS A DRUGS. Paragraph 18's chapeau covers the listed compounds, their salts and stereoisomeric forms, and preparations or products containing them. Section 2 defines a controlled drug as a substance or product specified in Part 1, 2 or 3 of the First Schedule (or anything containing one). S 323 states that it came into operation on 1 May 2014 and substituted Part I of the First Schedule; its original paragraph 18 item (11) expressly listed this substance. Subsequent schedule amendments inserted other items, and the current consolidation shows the listing as item (31); the latest inspected First Schedule amendment, S 321/2026, does not remove or alter it. The exact named substance and the applicable salt, stereoisomer and preparation/product coverage are therefore established directly, without analogue inference.

2-Aminoindane is the named substance 2,3-dihydro-1H-inden-2-amine. The 2017 Regulations came into operation on 4 May 2017 and Regulation 5(1) prohibits producing, supplying or offering to supply, and importing or exporting a controlled drug, subject to the Regulations. Schedule 1 paragraph 1(o) expressly names 2,3-dihydro-1H-inden-2-amine and covers specified phenyl-ring and nitrogen substitutions; paragraphs 2 to 5 extend coverage to stereoisomers, esters or ethers, salts, and preparations or other products containing covered substances. S.I. No. 121/2021 substituted Schedule 1 and retained the exact paragraph 1(o) entry and extensions. S.I. No. 405/2025 added other substances to Schedules 1 and 4 without amending paragraph 1(o). S.I. Nos. 9/2026 and 139/2026 amended Garda terminology and record-keeping/electronic-prescription provisions, respectively, without amending Schedule 1; S.I. No. 9/2026 states the collective citation is the Misuse of Drugs Regulations 2017 to 2026, and S.I. No. 139/2026 states that the collective citation includes it and commenced on 30 June 2026.

As of 26 August 2026, the official Polish schedule covers 2-aminoindane through the exact listed synonym 2-indanoamina (2A-I) and the corresponding structural/chemical designation 2,3-dihydro-1H-inden-2-amina in Annex 1, Group I-P. Under Article 33(2) of the Act on Counteracting Drug Addiction, Group I-P psychotropic substances may be used only for research. Article 34(1) limits possession of psychotropic substances to an authorized entrepreneur, organizational unit, or individual under the Act or the specified EU regulations. The 30 April 2025 amendment changes Group I-P item 7 and adds other entries, but does not amend item 1/2A-I. The 7 July 2026 amendment expressly identifies the underlying regulation as Dz.U. 2024 poz. 1139 and Dz.U. 2025 poz. 598, changes other schedule entries, and does not amend item 1/2A-I; it was published on 13 July 2026 and its 14-day commencement rule makes it effective on 28 July 2026. The latest Act amendment, Dz.U. 2026 poz. 1004, was not yet effective on 26 August 2026 and does not amend Articles 33 or 34. The prohibited status is therefore the schedule-based legal classification, subject to the research-use and authorized-possession limits.

The current Russian Government text for Resolution No. 1002 places this exact designation in List I, whose heading states that circulation in the Russian Federation is prohibited. The 2025 official amendment (Resolution No. 880) identifies the controlled-substances list as the list approved by Resolution No. 681 and confirms the current amended framework. Resolution No. 1002 gives this entry thresholds of over 0.05 g (significant), over 0.25 g (large), and over 500 g (especially large) for the specified Criminal Code provisions. The derivative coverage is limited to derivatives not included as separate positions; no broader ester rule is asserted. The proposed 4 June 2012 date is not supported by the fetched current official texts and is omitted.

2-Aminoindane is the ring-closed indane analogue identified by PubChem CID 76310 as 2,3-dihydro-1H-inden-2-amine (SMILES C1C(CC2=CC=CC=C21)N). The last accessible official consolidated schedule (01 August 2025) places beta-aminopropylbenzene and beta-aminoisopropylbenzene derivatives in Schedule 6 where structurally derived by side-chain substitution or ring closure. SAHPRA's current first-party page identifies the July 2026 Consolidated Schedules (Version 1, date updated 06/07/2026) as the latest version and marks the August 2025 PDF archived and DO NOT USE. The current PDF download is hosted on SAHPRA's SharePoint link, which returned HTTP 403 in this check. SAHPRA's amended-schedules index identifies Government Notice 7446 (Government Gazette 54627, 08/05/2026) as the latest amendment; the official Gazette text amends Schedule 4 only by inserting yohimbine for veterinary use and does not amend Schedule 6. Accordingly, the explicit Schedule 6 ring-closure clause in the last operative consolidation carries into the current July 2026 consolidation; the archived PDF is used as historical text evidence, not as the current instrument.